AstraZeneca PLC filings document the disclosures of a foreign private issuer focused on prescription medicines across oncology, rare diseases, cardiovascular, renal and metabolism, respiratory, and immunology. The company’s Form 6-K reports include quarterly operating results, product sales, alliance and collaboration revenue, EPS measures, and management commentary on medicine performance and pipeline progress.
Other filings record FDA advisory-committee and approval updates for medicines such as TRUQAP, BREZTRI, SAPHNELO, camizestrant, and ULTOMIRIS; Phase III trial disclosures; licensing arrangements; Board changes; total voting rights; and admission of additional ordinary shares. These documents also provide capital-structure and governance information relevant to AstraZeneca’s UK issuer framework and SEC foreign-issuer reporting obligations.
AstraZeneca PLC (AZN) officer Mani Sharma, whose stated role is SVP, Group Controller and Head of Global Finance Services, acquired 2 ordinary shares on October 6, 2026, pursuant to the issuer’s Share Incentive Plan. The disclosed price was GBP120.75 per share, converted to $159.80 at GBP1.0000 to $1.3234 on October 2, 2026. After the acquisition, Sharma directly held 19,290.6989 ordinary shares.
AstraZeneca PLC (AZN) completed its $2 billion equity investment in Summit Therapeutics. AstraZeneca said the investment will accelerate development of ivonescimab, a first-in-class bispecific antibody targeting PD-1 and VEGF, in combination with antibody drug conjugates (ADCs) across tumour types.
AstraZeneca and Summit have also entered a clinical collaboration agreement to evaluate sonesitatug vedotin (Sone-V) with ivonescimab. They intend to enter an additional agreement for a global development programme combining other AstraZeneca cancer medicines, including additional ADCs, with ivonescimab. Separately, AstraZeneca and Daiichi Sankyo entered a clinical collaboration with Summit to evaluate Datroway (datopotamab deruxtecan) with ivonescimab across multiple tumour types, including lung and breast cancers.
AstraZeneca PLC, Daiichi Sankyo and Summit Therapeutics Inc. have entered into a clinical collaboration to evaluate Datroway (datopotamab deruxtecan) with ivonescimab across multiple tumour types, including lung and breast cancers. The companies intend to begin with a Phase III trial in first-line triple-negative breast cancer.
Each company will contribute its medicine to the planned combination trials, which will be sponsored by AstraZeneca or Daiichi Sankyo. All three companies will contribute to trial costs and retain development and commercial rights to their respective medicines.
AstraZeneca PLC issued and admitted 9,828 ordinary shares of $0.25 each under its employee share schemes for September 1, 2026, to September 30, 2026. The shares are fully fungible with existing ordinary shares and were admitted to trading on the London Stock Exchange Main Market under the existing block admission dated January 29, 2021.
AstraZeneca PLC (AZN) reported 1,551,053,289 total voting rights as of September 30, 2026, corresponding to issued ordinary shares of US$0.25 each. No shares were held in treasury. Shareholders may use the voting-rights total as the denominator for determining whether they must notify the company of an interest, or a change in an interest, under the Financial Conduct Authority’s Disclosure and Transparency Rules.
AstraZeneca PLC (AZN) has agreed to invest $2 billion in newly issued equity in Summit Therapeutics to support development of ivonescimab in combination with antibody drug conjugates. The investment is for approximately 109 thousand preferred shares, convertible into common stock at a 1:1,000 ratio. Following completion, AstraZeneca will hold rights equivalent to approximately 12.0% of Summit’s outstanding common stock, or approximately 10.6% on a fully diluted basis. Closing is anticipated within one week; future conversion is subject to customary regulatory clearances.
Under a separate clinical collaboration, the companies plan to evaluate Sone-Ve with ivonescimab in gastrointestinal cancers and intend to initiate trials imminently. Each company will contribute its medicine and jointly contribute trial costs, while retaining development and commercial rights to its respective medicine. A memorandum of understanding records their intent to enter a global development agreement combining ivonescimab with AstraZeneca cancer medicines, including additional ADCs.
AstraZeneca PLC (AZN) said the European Commission approved Trixeo Aerosphere as a maintenance treatment for asthma in EU patients aged 12 years and older whose condition is not adequately controlled by medium-dose inhaled corticosteroid (ICS) plus long-acting beta2-agonist (LABA) therapy. AstraZeneca describes it as the first and only triple-combination therapy approved in the EU for patients 12 and older, independent of exacerbation history.
The approval followed a positive opinion from the EMA’s Committee for Medicinal Products for Human Use and was based on Phase III KALOS and LOGOS results. The trials showed statistically significant lung-function improvements versus combined ICS/LABA comparators; their pooled analysis also showed a statistically significant reduction in the annualised rate of severe asthma exacerbations, including among patients with no exacerbations in the prior year. No new safety or tolerability signals were identified. Trixeo is a maintenance therapy, not a treatment for sudden breathing problems, and does not replace a rescue inhaler.
AstraZeneca PLC (AZN), through its Alexion Rare Disease unit, reports that the European Medicines Agency’s CHMP has recommended Klygefa (gefurulimab) for approval in the EU as an add-on treatment for adults with anti‑AChR antibody-positive generalised myasthenia gravis (gMG), based on the Phase III PREVAIL trial.
The study in 260 patients across 20 countries showed Klygefa met its primary endpoint, improving Myasthenia Gravis Activities of Daily Living (MG‑ADL) total score at week 26 versus placebo with a treatment difference of -1.6 (95% CI: -2.4, -0.8; p<0.0001), with clinically meaningful benefits seen from week one and sustained through week 26. If approved, Klygefa would be the first and only dual-binding nanobody C5 inhibitor for gMG in the EU, offering once‑weekly subcutaneous self-administration as an add-on to standard therapy, and was generally well-tolerated with a safety profile consistent with existing C5 inhibitors.
AstraZeneca PLC (AZN) reports that Enhertu, developed with Daiichi Sankyo, has received a positive opinion from the European Medicines Agency’s CHMP as a monotherapy adjuvant treatment for adults with resected HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2-targeted therapy. The opinion is based on the Phase III DESTINY-Breast05 trial, where Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1, with a hazard ratio of 0.47. At three years, 92.4% of patients on Enhertu were alive and free of invasive disease compared with 83.7% on T-DM1, and the safety profile was consistent with prior experience. Enhertu is already approved in multiple countries for several HER2-driven breast, lung, gastric and solid tumour indications, and this EU adjuvant recommendation extends its potential role into earlier-stage HER2-positive breast cancer.
AstraZeneca PLC (AZN) reports that Chief Executive Officer Pascal Soriot purchased additional equity in the company. On September 14, 2026, Soriot bought 60,000 AstraZeneca Ordinary Shares with a nominal value of US$0.25 each at a price of £121.02 per share on the LON market. The transaction is disclosed as a purchase by a Person Discharging Managerial Responsibilities in accordance with the EU Market Abuse Regulation as it forms part of UK law.